vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Stabilis Solutions, Inc. (SLNG). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $13.3M, roughly 1.1× Stabilis Solutions, Inc.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -2.0%, a 3.8% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -23.3%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-2.5M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -18.1%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Stabilis Solutions, Inc.SLNGEarnings & Financial Report
Stabilis Solutions, Inc. is a leading North American small-scale liquefied natural gas (LNG) producer and distributor. It supplies LNG fuel, cryogenic services, and full-cycle energy solutions to industrial, remote power, transportation, and commercial clients across the United States and Canada, advancing low-emission energy transition efforts.
CSBR vs SLNG — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $13.3M |
| Net Profit | $268.0K | $-262.0K |
| Gross Margin | 51.7% | 24.7% |
| Operating Margin | 1.2% | -2.4% |
| Net Margin | 1.8% | -2.0% |
| Revenue YoY | 11.5% | -23.3% |
| Net Profit YoY | -63.2% | -112.4% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $13.3M | ||
| Q3 25 | $14.0M | $20.3M | ||
| Q2 25 | $12.4M | $17.3M | ||
| Q1 25 | $17.0M | $17.3M | ||
| Q4 24 | $13.5M | $17.3M | ||
| Q3 24 | $14.1M | $17.6M | ||
| Q2 24 | $14.0M | $18.6M | ||
| Q1 24 | $12.0M | $19.8M |
| Q4 25 | $268.0K | $-262.0K | ||
| Q3 25 | $-436.0K | $1.1M | ||
| Q2 25 | $-1.8M | $-613.0K | ||
| Q1 25 | $4.5M | $-1.6M | ||
| Q4 24 | $728.0K | $2.1M | ||
| Q3 24 | $1.3M | $997.0K | ||
| Q2 24 | $-109.0K | $27.0K | ||
| Q1 24 | $-2.5M | $1.5M |
| Q4 25 | 51.7% | 24.7% | ||
| Q3 25 | 42.9% | 27.6% | ||
| Q2 25 | 41.1% | 26.5% | ||
| Q1 25 | 61.2% | 26.2% | ||
| Q4 24 | 44.9% | 28.5% | ||
| Q3 24 | 49.7% | 28.3% | ||
| Q2 24 | 48.2% | 27.1% | ||
| Q1 24 | 34.7% | 31.6% |
| Q4 25 | 1.2% | -2.4% | ||
| Q3 25 | -3.8% | 5.5% | ||
| Q2 25 | -16.2% | -2.4% | ||
| Q1 25 | 26.4% | -9.7% | ||
| Q4 24 | 5.4% | 12.8% | ||
| Q3 24 | 9.5% | 5.0% | ||
| Q2 24 | -1.9% | 2.4% | ||
| Q1 24 | -21.4% | 7.8% |
| Q4 25 | 1.8% | -2.0% | ||
| Q3 25 | -3.1% | 5.5% | ||
| Q2 25 | -14.9% | -3.5% | ||
| Q1 25 | 26.4% | -9.2% | ||
| Q4 24 | 5.4% | 12.2% | ||
| Q3 24 | 9.3% | 5.7% | ||
| Q2 24 | -0.8% | 0.1% | ||
| Q1 24 | -21.1% | 7.4% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.03 | $0.06 | ||
| Q2 25 | $-0.12 | $-0.03 | ||
| Q1 25 | $0.31 | $-0.09 | ||
| Q4 24 | $0.05 | $0.12 | ||
| Q3 24 | $0.09 | $0.05 | ||
| Q2 24 | $-0.01 | $0.00 | ||
| Q1 24 | $-0.19 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $7.5M |
| Total DebtLower is stronger | — | $7.9M |
| Stockholders' EquityBook value | $4.2M | $66.7M |
| Total Assets | $30.2M | $83.1M |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $7.5M | ||
| Q3 25 | $10.3M | $10.3M | ||
| Q2 25 | $9.8M | $12.2M | ||
| Q1 25 | $3.2M | $9.0M | ||
| Q4 24 | $2.8M | $9.0M | ||
| Q3 24 | $2.9M | $12.4M | ||
| Q2 24 | $2.6M | $11.5M | ||
| Q1 24 | $4.5M | $8.3M |
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $8.9M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | — | $8.6M | ||
| Q1 24 | — | $9.1M |
| Q4 25 | $4.2M | $66.7M | ||
| Q3 25 | $3.5M | $66.7M | ||
| Q2 25 | $3.8M | $65.5M | ||
| Q1 25 | $5.5M | $65.9M | ||
| Q4 24 | $681.0K | $67.0M | ||
| Q3 24 | $-332.0K | $65.4M | ||
| Q2 24 | $-1.9M | $63.7M | ||
| Q1 24 | $-2.1M | $63.2M |
| Q4 25 | $30.2M | $83.1M | ||
| Q3 25 | $30.5M | $87.1M | ||
| Q2 25 | $32.3M | $83.2M | ||
| Q1 25 | $30.6M | $83.1M | ||
| Q4 24 | $25.2M | $85.6M | ||
| Q3 24 | $24.9M | $89.3M | ||
| Q2 24 | $26.1M | $82.6M | ||
| Q1 24 | $26.8M | $80.6M |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $669.0K |
| Free Cash FlowOCF − Capex | $-2.0M | $-2.5M |
| FCF MarginFCF / Revenue | -13.1% | -18.6% |
| Capex IntensityCapex / Revenue | 1.6% | 23.7% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $462.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $669.0K | ||
| Q3 25 | $600.0K | $2.4M | ||
| Q2 25 | $6.9M | $4.5M | ||
| Q1 25 | $490.0K | $1.0M | ||
| Q4 24 | $-283.0K | $2.2M | ||
| Q3 24 | $311.0K | $2.6M | ||
| Q2 24 | $-1.8M | $5.0M | ||
| Q1 24 | $-919.0K | $3.9M |
| Q4 25 | $-2.0M | $-2.5M | ||
| Q3 25 | $554.0K | $-1.5M | ||
| Q2 25 | $6.6M | $3.9M | ||
| Q1 25 | $448.0K | $538.0K | ||
| Q4 24 | $-377.0K | $-3.4M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | $-1.8M | $3.7M | ||
| Q1 24 | $-1.0M | $3.1M |
| Q4 25 | -13.1% | -18.6% | ||
| Q3 25 | 4.0% | -7.3% | ||
| Q2 25 | 53.5% | 22.4% | ||
| Q1 25 | 2.6% | 3.1% | ||
| Q4 24 | -2.8% | -19.7% | ||
| Q3 24 | — | 7.1% | ||
| Q2 24 | -13.0% | 19.7% | ||
| Q1 24 | -8.4% | 15.5% |
| Q4 25 | 1.6% | 23.7% | ||
| Q3 25 | 0.3% | 19.1% | ||
| Q2 25 | 2.0% | 3.7% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | 0.7% | 32.3% | ||
| Q3 24 | 0.0% | 7.4% | ||
| Q2 24 | 0.0% | 7.4% | ||
| Q1 24 | 0.8% | 4.4% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 2.14× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 1.03× | ||
| Q3 24 | 0.24× | 2.56× | ||
| Q2 24 | — | 186.59× | ||
| Q1 24 | — | 2.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
SLNG
| Natural Gas Gathering Transportation Marketing And Processing | $11.1M | 84% |
| Other | $1.3M | 10% |
| Services | $897.0K | 7% |
